title: Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report.
abstract: A case study using mammalian target of rapamycin complex 1 in recurrent ovarian clear cell carcinoma (CCC) was recently conducted. We report our experience with a patient suffering from recurrent ovarian CCC who achieved long-term disease control with everolimus administration. The patient was a 53-year-old woman who was diagnosed with recurrent ovarian CCC with dissemination throughout the abdominal cavity. Previously, she had received three chemotherapy regimens, but the disease was progressive and she showed no response to treatment. Therefore, oral everolimus administration (everolimus 10 mg/day on days 1-28, a 28-day period comprised one cycle) was started. She was administered six cycles. The antitumor response was stable disease, and grade 3 anemia was observed. Chemotherapy was then switched to gemcitabine/docetaxel therapy. In the middle of the second cycle, a rapid increase in ascitic fluid and CA125 elevation were observed. Thereafter, the patient received best supportive care and died of the disease. Everolimus may inhibit malignant progression of ovarian CCC.
authors: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
authors: Eriko
authors: E
authors: Takatori
authors: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
authors: Tadahiro
authors: T
authors: Shoji
authors: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
authors: Yuki
authors: Y
authors: Miura
authors: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
authors: Anna
authors: A
authors: Takada
authors: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
authors: Satoshi
authors: S
authors: Takeuchi
authors: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
authors: Toru
authors: T
authors: Sugiyama
keywords: mTORC1; ovarian cancer; palliative chemotherapy